Canada markets close in 9 minutes

Kane Biotech Inc. (KNE.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.0800-0.0050 (-5.88%)
As of 02:45PM EST. Market open.
Full screen
Previous Close0.0850
Open0.0900
Bid0.0750 x 0
Ask0.0850 x 0
Day's Range0.0800 - 0.0900
52 Week Range0.0500 - 0.1500
Volume61,000
Avg. Volume35,507
Market Cap10.548M
Beta (5Y Monthly)0.47
PE Ratio (TTM)N/A
EPS (TTM)-0.0300
Earnings DateNov 28, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Kane Biotech Announces Improved Third Quarter 2023 Financial Results

    29% Increase in Product and Services Revenue; 26% Increase in Total RevenueWINNIPEG, Manitoba, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its third quarter 2023 financial results. Third Quarter Financial Highlights: Revenue from product and services for the three months ended September 30, 2023 was $548,785 an increase of 29% from $425,671 in the three months ended September 30, 2022. This increase is due mainly

  • GlobeNewswire

    Kane Biotech to Release Third Quarter 2023 Financial Results on November 28, 2023 – Conference Call to Follow

    WINNIPEG, Manitoba, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its third quarter 2023 financial results after market close on Tuesday, November 28, 2023. Kane Biotech management will host a conference call at 4:30 p.m. ET to review the financial results and di

  • GlobeNewswire

    Kane Biotech Strengthens Board with Biotech Executive

    Accomplished executive with over two decades of senior biotechnology expertise joins Kane’s Board of DirectorsWINNIPEG, Manitoba, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) is pleased to announce that John Coleman has been appointed to the Board of Directors of Kane Biotech effective immediately. Dr. Coleman brings a wealth of scientific and business expertise to the board. Currently serving as the President and CEO of